Metabolic Syndrome

What is Metabolic Syndrome?

Metabolic syndrome is not a single disease but a constellation of interrelated metabolic abnormalities that occur together. The presence of metabolic syndrome dramatically increases the risk of type 2 diabetes and cardiovascular disease—making it a key target for metabolic peptide therapies.

Key concept: Metabolic syndrome represents a state of systemic metabolic dysfunction, with insulin resistance as the underlying driver.

Diagnostic Criteria

Metabolic syndrome is diagnosed when 3 or more of the following are present:

Component	Threshold
Abdominal obesity	Waist ≥40 inches (men), ≥35 inches (women)
Elevated triglycerides	≥150 mg/dL (or on treatment)
Reduced HDL cholesterol	Under 40 mg/dL (men), Under 50 mg/dL (women)
Elevated blood pressure	≥130/85 mmHg (or on treatment)
Elevated fasting glucose	≥100 mg/dL (or on treatment)

Criteria from NCEP ATP III; other definitions (IDF, WHO) have minor variations

The Underlying Connection

Insulin resistance is the common thread:

Insulin Resistance
    ↓
├── Hyperinsulinemia → Sodium retention → Hypertension
├── Dyslipidemia → Increased VLDL → High triglycerides, low HDL
├── Impaired glucose disposal → Hyperglycemia
└── Adipose dysfunction → Visceral fat accumulation

Prevalence

• ~35% of US adults meet criteria
• Prevalence increases with age
• More common in certain ethnic groups
• Rising globally with obesity epidemic

Health Risks

Condition	Relative Risk Increase
Type 2 diabetes	5-fold
Cardiovascular disease	2-fold
Stroke	2-fold
MASH (fatty liver)	3-5 fold
Chronic kidney disease	1.5-fold

Why Metabolic Syndrome Matters for Peptide Research

GLP-1 agonists and dual agonists improve multiple components:

Component	Effect of GLP-1/Dual Agonists
Waist circumference	↓↓ (via weight loss)
Triglycerides	↓ (10-20% reduction)
HDL cholesterol	↑ (modest increase)
Blood pressure	↓ (5-10 mmHg systolic)
Fasting glucose	↓↓ (major effect)

Clinical trial data:

Medication	Resolution of MetS
Tirzepatide 15 mg	~50% of patients
Semaglutide 2.4 mg	~40% of patients

Pathophysiology

Adipose Tissue Dysfunction

Central to metabolic syndrome:

• Visceral fat produces inflammatory cytokines
• Free fatty acids released → lipotoxicity
• Reduced adiponectin → impaired insulin signaling
• Pro-inflammatory state

Hepatic Effects

• Increased hepatic glucose production
• Reduced glycogen synthesis
• VLDL overproduction → dyslipidemia
• Fatty liver development

Vascular Effects

• Endothelial dysfunction
• Increased sympathetic activity
• Sodium and water retention
• Arterial stiffness

Treatment Approach

Lifestyle (foundation):

• Weight loss (5-10% dramatically improves)
• Physical activity
• Dietary modification
• Smoking cessation

Pharmacological:

• Address each component as needed
• GLP-1 agonists increasingly first-line
• SGLT2 inhibitors for glucose/CV benefit
• Statins for lipids
• Antihypertensives for BP

Peptides Addressing Metabolic Syndrome

Peptide	Status	Effect on MetS
Semaglutide	Approved	Improves all components
Tirzepatide	Approved	Most comprehensive effect
Retatrutide	Phase 3	Potentially superior

---

This entry is for educational purposes only. Metabolic syndrome management should be individualized by a healthcare provider.